Peroxisome proliferator-activated receptor-γ coactivator-1α activation of CYP7A1 during food restriction and diabetes is still inhibited by small heterodimer partner

Dong J. Shin, Timothy Osborne

Research output: Contribution to journalArticle

Abstract

Cholesterol 7α-hydroxylase (CYP7A1) catalyzes the rate-limiting step in the classic pathway of hepatic bile acid biosynthesis from cholesterol. During fasting and in type I diabetes, elevated levels of peroxisome proliferator-activated receptor γ-coactivator-1α (PGC-1α) induce expression of the Cyp7A1 gene and overexpression of PGC-1α in hepatoma cells stimulates bile acid synthesis. Using Ad-PGC-1α-RNA interference to induce acute disruption of PGC-1α in mice, here we show that PGC-1α is necessary for fasting-mediated induction of CYP7A1. Co-immunoprecipitation and promoter activation studies reveal that the induction of CYP7A1 is mediated by direct interaction between PGC-1α and the AF2 domain of liver receptor homolog-1 (LRH-1). In contrast, the very similar PGC-1β could not substitute for PGC-1α. We also show that transactivation of PGC-1α and LRH-1 is repressed by the small heterodimer partner (SHP). Treatment of mice with GW4064, a synthetic agonist for farnesoid X receptor, induced SHP expression and decreased both the recruitment of PGC-1α to the Cyp7A1 promoter and the fasting-induced expression of CYP7A1 mRNA. These data suggest that PGC-1α is an important co-activator for LRH-1 and that SHP targets the interaction between LRH-1 and PGC-1α to inhibit CYP7A1 expression. Overall, these studies provide further evidence for the important role of PGC-1α in bile acid homeostasis and suggest that pharmacological targeting of farnesoid X receptor in vivo can be used to reverse the increase in CYP7A1 associated with adverse metabolic conditions.

Original languageEnglish (US)
Pages (from-to)15089-15096
Number of pages8
JournalJournal of Biological Chemistry
Volume283
Issue number22
DOIs
StatePublished - May 30 2008
Externally publishedYes

Fingerprint

Peroxisome Proliferator-Activated Receptors
Medical problems
Liver
Bile Acids and Salts
Chemical activation
Food
Fasting
Cholesterol 7-alpha-Hydroxylase
Biosynthesis
RNA Interference
Type 1 Diabetes Mellitus
Immunoprecipitation
Genes
Cholesterol
Transcriptional Activation
RNA
Hepatocellular Carcinoma
Homeostasis
Messenger RNA
Pharmacology

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

@article{8ddbf146d2bb425bb260f9ae8b22386c,
title = "Peroxisome proliferator-activated receptor-γ coactivator-1α activation of CYP7A1 during food restriction and diabetes is still inhibited by small heterodimer partner",
abstract = "Cholesterol 7α-hydroxylase (CYP7A1) catalyzes the rate-limiting step in the classic pathway of hepatic bile acid biosynthesis from cholesterol. During fasting and in type I diabetes, elevated levels of peroxisome proliferator-activated receptor γ-coactivator-1α (PGC-1α) induce expression of the Cyp7A1 gene and overexpression of PGC-1α in hepatoma cells stimulates bile acid synthesis. Using Ad-PGC-1α-RNA interference to induce acute disruption of PGC-1α in mice, here we show that PGC-1α is necessary for fasting-mediated induction of CYP7A1. Co-immunoprecipitation and promoter activation studies reveal that the induction of CYP7A1 is mediated by direct interaction between PGC-1α and the AF2 domain of liver receptor homolog-1 (LRH-1). In contrast, the very similar PGC-1β could not substitute for PGC-1α. We also show that transactivation of PGC-1α and LRH-1 is repressed by the small heterodimer partner (SHP). Treatment of mice with GW4064, a synthetic agonist for farnesoid X receptor, induced SHP expression and decreased both the recruitment of PGC-1α to the Cyp7A1 promoter and the fasting-induced expression of CYP7A1 mRNA. These data suggest that PGC-1α is an important co-activator for LRH-1 and that SHP targets the interaction between LRH-1 and PGC-1α to inhibit CYP7A1 expression. Overall, these studies provide further evidence for the important role of PGC-1α in bile acid homeostasis and suggest that pharmacological targeting of farnesoid X receptor in vivo can be used to reverse the increase in CYP7A1 associated with adverse metabolic conditions.",
author = "Shin, {Dong J.} and Timothy Osborne",
year = "2008",
month = "5",
day = "30",
doi = "10.1074/jbc.M710452200",
language = "English (US)",
volume = "283",
pages = "15089--15096",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "22",

}

TY - JOUR

T1 - Peroxisome proliferator-activated receptor-γ coactivator-1α activation of CYP7A1 during food restriction and diabetes is still inhibited by small heterodimer partner

AU - Shin, Dong J.

AU - Osborne, Timothy

PY - 2008/5/30

Y1 - 2008/5/30

N2 - Cholesterol 7α-hydroxylase (CYP7A1) catalyzes the rate-limiting step in the classic pathway of hepatic bile acid biosynthesis from cholesterol. During fasting and in type I diabetes, elevated levels of peroxisome proliferator-activated receptor γ-coactivator-1α (PGC-1α) induce expression of the Cyp7A1 gene and overexpression of PGC-1α in hepatoma cells stimulates bile acid synthesis. Using Ad-PGC-1α-RNA interference to induce acute disruption of PGC-1α in mice, here we show that PGC-1α is necessary for fasting-mediated induction of CYP7A1. Co-immunoprecipitation and promoter activation studies reveal that the induction of CYP7A1 is mediated by direct interaction between PGC-1α and the AF2 domain of liver receptor homolog-1 (LRH-1). In contrast, the very similar PGC-1β could not substitute for PGC-1α. We also show that transactivation of PGC-1α and LRH-1 is repressed by the small heterodimer partner (SHP). Treatment of mice with GW4064, a synthetic agonist for farnesoid X receptor, induced SHP expression and decreased both the recruitment of PGC-1α to the Cyp7A1 promoter and the fasting-induced expression of CYP7A1 mRNA. These data suggest that PGC-1α is an important co-activator for LRH-1 and that SHP targets the interaction between LRH-1 and PGC-1α to inhibit CYP7A1 expression. Overall, these studies provide further evidence for the important role of PGC-1α in bile acid homeostasis and suggest that pharmacological targeting of farnesoid X receptor in vivo can be used to reverse the increase in CYP7A1 associated with adverse metabolic conditions.

AB - Cholesterol 7α-hydroxylase (CYP7A1) catalyzes the rate-limiting step in the classic pathway of hepatic bile acid biosynthesis from cholesterol. During fasting and in type I diabetes, elevated levels of peroxisome proliferator-activated receptor γ-coactivator-1α (PGC-1α) induce expression of the Cyp7A1 gene and overexpression of PGC-1α in hepatoma cells stimulates bile acid synthesis. Using Ad-PGC-1α-RNA interference to induce acute disruption of PGC-1α in mice, here we show that PGC-1α is necessary for fasting-mediated induction of CYP7A1. Co-immunoprecipitation and promoter activation studies reveal that the induction of CYP7A1 is mediated by direct interaction between PGC-1α and the AF2 domain of liver receptor homolog-1 (LRH-1). In contrast, the very similar PGC-1β could not substitute for PGC-1α. We also show that transactivation of PGC-1α and LRH-1 is repressed by the small heterodimer partner (SHP). Treatment of mice with GW4064, a synthetic agonist for farnesoid X receptor, induced SHP expression and decreased both the recruitment of PGC-1α to the Cyp7A1 promoter and the fasting-induced expression of CYP7A1 mRNA. These data suggest that PGC-1α is an important co-activator for LRH-1 and that SHP targets the interaction between LRH-1 and PGC-1α to inhibit CYP7A1 expression. Overall, these studies provide further evidence for the important role of PGC-1α in bile acid homeostasis and suggest that pharmacological targeting of farnesoid X receptor in vivo can be used to reverse the increase in CYP7A1 associated with adverse metabolic conditions.

UR - http://www.scopus.com/inward/record.url?scp=47249161697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249161697&partnerID=8YFLogxK

U2 - 10.1074/jbc.M710452200

DO - 10.1074/jbc.M710452200

M3 - Article

C2 - 18385139

AN - SCOPUS:47249161697

VL - 283

SP - 15089

EP - 15096

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 22

ER -